This trial is testing a new cancer drug to see if it is safe and effective in people with relapsed or refractory T or B cell malignancies.
- T-Cell Lymphoma
2 Primary · 2 Secondary · Reporting Duration: From CTX130 infusion up to 60 months post-infusion]
1 Treatment Group
1 of 1
45 Total Participants · 1 Treatment Group
Primary Treatment: CTX130 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are currently partaking in this clinical experiment?
"This trial necessitates the recruitment of 45 volunteers who adhere to its inclusion criteria. Potential participants can join at any one of two primary research sites - Duarte, California and Houston, Texas." - Anonymous Online Contributor
Are there any clinical research centers in North America conducting this trial?
"Presently, this trial is operating from 9 distinct sites. These locations include Duarte, Houston and Salt Lake City as well as 6 other places of residence. It would be most beneficial to select the closest location in order to limit any possible travelling inconveniences should you choose to take part." - Anonymous Online Contributor
Is there still capacity to enroll individuals in this experiment?
"Affirmative. Clinicaltrials.gov provides evidence that this experiment is presently recruiting participants, which it has been doing since July 31st 2020. 45 applicants are desired from 9 separate locations for the trial's duration." - Anonymous Online Contributor
Has the FDA given its stamp of approval for CTX130?
"As this is an early-stage trial, the safety of CTX130 has been evaluated as a 1 on Power's scale. This rating indicates that there is limited data available to assess its efficacy and safety." - Anonymous Online Contributor